EPO Deficiency Upregulates GADD45b/p38 MAPK Axis, Mediating Schizophrenia‐Related Synaptic and Cognitive Impairments
2024

EPO Deficiency and Cognitive Impairments in Schizophrenia

Sample size: 36 publication 10 minutes Evidence: high

Author Information

Author(s): Guo Cuiping, Li Wensheng, Liu Yi, Tao Xiaoqing, Mahaman Yacoubou Abdoul Razak, Wang Jianzhi, Liu Rong, Li Shusheng, Wang Xiaochuan

Primary Institution: Huazhong University of Science and Technology

Hypothesis

EPO deficiency contributes to cognitive impairments in schizophrenia through the GADD45b/p38 MAPK axis.

Conclusion

EPO deficiency leads to cognitive impairments in schizophrenia by upregulating GADD45b and activating the p38 MAPK pathway.

Supporting Evidence

  • EPO levels were significantly decreased in schizophrenia patients.
  • EPO supplementation mitigated cognitive impairments in a rat model.
  • Overexpression of GADD45b exacerbated cognitive impairments.
  • Downregulation of GADD45b rescued cognitive deficits.
  • Inhibition of p38 MAPK reduced synaptic damage.
  • Behavioral tests showed improved memory with EPO treatment.
  • RNA sequencing revealed increased GADD45b expression in SZ rats.
  • KEGG analysis indicated activation of the p38 MAPK pathway.

Takeaway

When a brain chemical called EPO is low, it can cause problems with thinking and memory in people with schizophrenia.

Methodology

The study used a rat model of schizophrenia induced by MK801 to investigate the effects of EPO deficiency on cognitive impairments and synaptic function.

Limitations

The study was conducted in a rat model, which may not fully replicate human conditions.

Participant Demographics

Male Sprague-Dawley rats, 8 weeks old.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/advs.202406979

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication